Computational Target Prioritization

Insilico Medicine’s AI-identified drug candidate, rentosertib, targeting idiopathic pulmonary fibrosis (IPF), has advanced to Phase III trials. Rentosertib, which inhibits TNIK, demonstrated significant FVC improvement in a Phase IIa trial. The drug’s discovery and development pipeline, powered by Insilico’s Pharma.AI platform, involved AI-driven target prioritization and generative molecular engineering, achieving preclinical nomination in just 18 months. This progression validates the potential of AI in revolutionizing drug discovery by accelerating timelines and originating novel therapeutic opportunities.